
ãæ¥œåãã©ãªãšçްèã®å¥è·¡â¡ã
ââ è¡ç³å€ããäžããããããçããããžã5-ALAã瀺ãããå šãæ°ããã¢ãããŒã ââ
â»æ¬èšäºã¯ãæµ·å€ã§è¡ãããŠããç¹å®ã®æåã«é¢ããèšåºç ç©¶ããã³æ²»éšã®äºå®ã玹ä»ãããã®ã§ãããæ¥æ¬åœå ã«ãããç¹å®ã®ãµããªã¡ã³ãã®å¹æå¹èœãæšæŠã»ä¿èšŒãããã®ã§ã¯ãããŸããã
ãæ¥œåãã©ãªãšçްèã®å¥è·¡â ãã¯ãã¡ãã
â¶ïžã第1åãªã³ã¯ã
â ã¯ããã«
ååããã©ãªãšããçŸããå³¶åœããæ¥æ¿ãªé£ã®æ¬§ç±³åã«ãã£ãŠãäžç屿ã®å¥åº·å±æ©ïŒç³ä»£è¬ã®èª²é¡ïŒããžãšçŽé¢ããŠããŸã£ãçµç·¯ããäŒãããŸããã
ãããŠä»åãããããæ¬é¡ãžãæ¥æ¬ã®ãã€ãªãã¯ãããžãŒããŒã ããã©ãªæ¿åºã«æç€ºãããå šãæ°ããã¢ãããŒããã®æ žå¿ã«è¿«ããŸãã
â â ãäº€éæŽçããããççŒããžãšãããçºæ³ã®å€§è»¢æ
ãŸããåŸæ¥ã®äžè¬çãªã¢ãããŒãã®èãæ¹ãæŽçããŸããäœã«æº¢ããŠããŸã£ãç³ã«å¯ŸããŠè¡ãããŠããã®ã¯ãäžèšã§èšãã°ãè¡æ¶²äžã«æº¢ããç³ã®äº€éæŽçãã§ããç³ãå€ããããªãã现èã®äžã«ç¡çããæŒã蟌ããããã§ãäœããªããå€ãžæåºãããããã¯ãããŸã§ããç³ã溢ããŠããããšããçµæã«å¯Ÿããã¢ãããŒãã§ãã
ããããããã§æ ¹æ¬çãªåããçãŸããŸãã ããªããç³ãçãããããã«æº¢ããŠããŸãã®ãïŒã
è¿å¹Žã®ç ç©¶ã§ã¯ããããã課é¡ãåãªããæ°å€ã®ç æ°ãã§ã¯ãªããã现èã®ãšãã«ã®ãŒä»£è¬ã®ã·ã¹ãã ãšã©ãŒããšããŠæããèŠç¹ãåºãã£ãŠããŸããåé¡ã¯ãç³ãå€ãããããšãã ãã§ãªããã现èãç³ããšãã«ã®ãŒã«å€ããåïŒçããåïŒãèœã¡ãŠããããšãã«ããã®ã§ãã
ãã®çºæ³ã®è»¢æãããã5-ALAãæç€ºããæ°ããã¢ãããŒãã®åºçºç¹ã§ããã
â â¡ 5-ALAã®æ£äœã¯ãçåœã®ãå ã®ã¹ã€ãããã ã£ã
ããã§ã5-ALAãšããç©è³ªãã®ãã®ã«ã€ããŠãå°ãé©ããããªè©±ããããŠãã ããã
5-ALAïŒ5-ã¢ããã¬ããªã³é
žïŒã¯ãå®ã¯æ€ç©ããå
åæããè¡ãããã«äœãåºãç©è³ªã§ããèç·çŽ ïŒã¯ãããã£ã«ïŒã®ææã§ãããæ€ç©ã倪éœãšãã«ã®ãŒãååŠãšãã«ã®ãŒã«å€æããããã®ãããã°ãå
ã®ã¹ã€ããããšãªãååã§ãã
ãããŠãç§ãã¡äººéã®äœå
ã§ããå
šãåãç©è³ªãäœãããŠããŸããç§ãã¡ã®çްèã®çºé»æãããã³ã³ããªã¢ãããšãã«ã®ãŒã®æ žãšãªãæåïŒãã ïŒãåæããéã®åæãšããŠã5-ALAã¯äžå¯æ¬ ãªåœ¹å²ãæãããŠããŸããæ€ç©ã倪éœããçæãã«å€ããããã«ã人éã®ããã³ã³ããªã¢ã¯ç³ããçæãã«å€ããããã®å€æããã»ã¹ã®æ ¹å¹¹ã«ã5-ALAãšããå
±éã®ååãååšããŠããã®ã§ãããæ€ç©ã人éãããšãã«ã®ãŒãçã¿åºãä»çµã¿ã®ææã¯åãã ã£ããââãã®äºå®ã¯ãçåœã®ç¥ç§ãæãããããšåæã«ã5-ALAãžã®çè§£ãæ·±ããéèŠãªèŠç¹ã§ãã
â â¡-plus ãçºé µãã®åã§çãŸãã5-ALAãšãå¹çãé«ãããçžæ£ã
ããã²ãšã€ãããŸãç¥ãããŠããªãäºå®ããäŒãããŸãããã®5-ALAãå®å®çã«çç£ããããã«ãæ¥æ¬ã®ãã€ãªãã¯ãããžãŒã掻çšããŠããã®ãã埮çç©çºé µæè¡ãã§ããçŽè±ãå³åããšãŒã°ã«ããšåããçºé µãã®åçãå¿çšããç¹å®ã®åŸ®çç©ã®åãåããŠ5-ALAãè²ããšããæ¹æ³ã§ãããæå 端ã®ãã€ãªãã¯ãããžãŒããšèããšé ãååšã«æãããããããŸãããããã®è£œé ã®æ ¹åºã«ããã®ã¯ãæ¥æ¬äººã倿¥ãã芪ããã§ããçºé µã®ç¥æµã§ãããã®ã§ãã
ããã«ãç§åŠçã«ãšãŠãéèŠãªãã€ã³ãããããŸãã5-ALAãäœå ã§ãšãã«ã®ãŒä»£è¬ã®æ žïŒãã ïŒãžãšå€æãããéã«ã¯ããéåããšããã¿ãã³B6ããè£é µçŽ ãšããŠäžå¯æ¬ ã§ãã
5-ALAãæãéãéåïŒèµ€èº«ã®èã»ã¬ããŒãªã©ïŒããã¿ãã³B6ïŒãããã»é¶èã»çç±³ãªã©ïŒãæèããé£äºãšçµã¿åãããããšã§ãããå¹ççãªæŽ»çšãæåŸ ã§ããŸãã
ð¡ ããããã€ã³ã åŠè¡ç ç©¶ïŒâ»2ïŒã§ã¯ãã¯ãšã³é žç¬¬äžéãããªãŠã ããšããåžåçã®é«ã圢æ ã®éåãšã®çµã¿åããã䜿ãããŠããŸãããµããªã¡ã³ããéžã¶éã¯ãé åãããŠããéã®çš®é¡ã«ã泚ç®ããŠã¿ãŠãã ãããçŸä»£ã®åªãããµããªã¡ã³ãã«ã¯ããã®å¹çæ§ãæåããèšç®ããŠéåãããããããã©ã³ã¹ããé åãããŠãããã®ããããŸãã
â ãè£è¶³ããŒã¿ãé£äºããæãã«ã¯ãçŸå®çã§ã¯ãªãé
5-ALAã¯ã»ãããèãçŽè±ãèµ€ã¯ã€ã³ãªã©ã®çºé µé£åã«ã埮éã«å«ãŸããŠããŸããããããäžè¬çãªãµããªã¡ã³ã1ååïŒçŽ50mgïŒã®5-ALAãé£äºã ãã§è£ãããšãããšãèµ€ã¯ã€ã³ãªãçŽ8ãªããã«ïŒããã«11æ¬åïŒãçŽè±ãªãçŽ4,000ããã¯ïŒçŽ180kgïŒãšããéæ¹ããªãéãå¿ èŠã«ãªããšãã詊ç®ããããŸãïŒâ»ã¡ãŒã«ãŒè³æã«ãã詊ç®ïŒãã ãããããæå 端ã®çºé µãã¯ãããžãŒã«ããå¹ççãªè£çµŠãäžçäžã§æ³šç®ãããŠããã®ã§ãã
ãŸããç ç©¶ããŒã¿ïŒâ»1ïŒã«ãããšãç§ãã¡ã®äœå ã§äœããã5-ALAã®çç£éã¯ãå 霢ãšãšãã«äœäžããŠããããšã瀺ãããŠããŸããã幎霢ãšãšãã«ãªããšãªãå æ°ãäžãããªããããã£ããããªãããšæããèæ¯ã«ã¯ããã®äœå ã®5-ALAç£çäœäžãé¢ä¿ããŠããå¯èœæ§ãããã®ã§ãã
â ⢠ããã³ã³ããªã¢ã®ã補é ã©ã€ã³ãã§äœãèµ·ããŠããã®ã
ç³ããšãã«ã®ãŒã«å€ããããã»ã¹ããå·¥å Žã®è£œé ã©ã€ã³ã«äŸããŠã¿ãŸãããã
第1ã©ã€ã³ïŒè§£ç³ç³»ïŒïŒ ç³ããäžéçŽ æãã«åè§£ããã现èã®å€åŽïŒçްè質ïŒã®ç²å å·¥ã©ã€ã³ã
第2ã©ã€ã³ïŒTCAãµã€ã¯ã«ïŒïŒ äžéçŽ æãããã«ç²Ÿè£œãããšãã«ã®ãŒã®çŽ ãåãåºãããã³ã³ããªã¢å éšã®ç²Ÿå¯å å·¥ã©ã€ã³ã
第3ã©ã€ã³ïŒé»åäŒéç³»ïŒïŒ åãåºããçŽ ã䜿ã£ãŠãæçµè£œåã§ãããATPïŒçåœã®ãšãã«ã®ãŒé貚ïŒãã倧éçç£ããããã³ã³ããªã¢å èã®ã¡ã€ã³ã©ã€ã³ã
å®ã¯ãã®è£œé ã©ã€ã³ã®äžã§ãç§ãã¡ãçããããã®ãšãã«ã®ãŒã®çŽ90%ããæåŸã®ã第3ã©ã€ã³ãã§çç£ãããŸãããããŠ5-ALAããäœãããæåã¯ããã®ç¬¬3ã©ã€ã³ã®äžæ žéšåïŒè§ŠåªïŒãšããŠæ©èœããŠããã®ã§ãã
幎霢ãçæŽ»ç¿æ £ã®ä¹±ãã«ãã£ãŠããã³ã³ããªã¢ã®æ©èœãäœäžãããšããŸãã«ããšãã«ã®ãŒã®è£œé ã©ã€ã³ãã®ãã®ãèæœåã»çž®å°ããŠãããç¶æ ã«ãªããŸãã5-ALAã¯ããã®æ»ã£ãŠããŸã£ãã©ã€ã³ãåã³å匷ã皌åãããããã®ã貎éãªãã¹ã¿ãŒã¿ãŒããšããŠæåŸ ãå¯ããããŠããã®ã§ãã
â ⣠ãã©ãªæ²»éšã®å ·äœçãªå 容
ããããç§åŠçèæ¯ãæã£ãŠããã©ãªã§è¡ãããèšåºç ç©¶ã»æ²»éšã¯ã©ã®ãããªãã®ã ã£ãã®ã§ããããã
SBIããŒã«ãã£ã³ã°ã¹ãšãã©ãªæ¿åºã®ååã®ããšé²ãããããã®ãããžã§ã¯ãã¯ãå°åã®å¥åº·èª²é¡ãæ±ãã人ã ã察象ã«ã5-ALAãäžå®æéæåããŠããããä»£è¬ææšãç¶ç¶çã«èгå¯ãããšããåŠè¡çãªèšèšã§è¡ãããŸããã
泚ç®ãã¹ãã¯ããã®ãããžã§ã¯ããããµããªã¡ã³ãã®è²©å£²ä¿é²ãã§ã¯ãªãããã©ãªæ¿åºãåœå®¶ã®å»ç課é¡ãšããŠçå£ã«åãåã£ããå ¬çãªç ç©¶ããšããŠé²ãããããšããç¹ã§ããå°ããªå³¶åœã®éãããå»çãªãœãŒã¹ã®äžã§ãã现èã¬ãã«ããã®ä»£è¬ç°å¢ã®æ¹åããç®æããšãã匷ãæå¿ããã®ãããžã§ã¯ããåãããŸããã
â †治éšã§ç€ºãããå€å
æ²»éšã®çµæã«ã€ããŠã¯ãçŸæç¹ã§çºè¡šãããŠããåŠè¡ããŒã¿ã®ç¯å²å ã§ãäŒãããŸãã
äžéšã®å¯Ÿè±¡è ã«ãããŠã5-ALAæåæéäžã«å¥åº·ç¶æã代è¬ã«é¢ããææšãžã®ååããªã¢ãããŒãã芳å¯ãããããšãè«æïŒâ»2ïŒçã§å ±åãããŠããŸãããã ããããã¯åŠè¡ç 究段éã®ããŒã¿ã§ããããã¹ãŠã®äººã«åæ§ã®çµæãçŸããããšãä¿èšŒãããã®ã§ã¯ãããŸããã
ãŸããæ³šç®ãã¹ãã¯æ°å€ã®å€åã ãã§ã¯ãããŸãããåå è ããã¯ãæ¥ã ã®ç掻ã«ãããäœèª¿ãã³ã³ãã£ã·ã§ã³ã«é¢ããååããªææ³ã®å£°ãå¯ããããŸããã
æ°å€ãå€ããæã蟌ãã®ã§ã¯ãªããå åŽãããæ¯æ¥ã®ã³ã³ãã£ã·ã§ã³ãæŽããããšããã¢ãããŒãã®å¯èœæ§ã瀺ããããšã«ããã®ãããžã§ã¯ãã®å€§ããªæçŸ©ããããŸãã
â ⥠ãçããåããåãæ»ãããšã®æå³
æåŸã«ãå°ãèŠéãåºããŠèããŠã¿ãŸãããã
ããšãã«ã®ãŒãäžæãçã¿åºããªãããšããç¶æ ã¯ãé ãåœã®äººã ã ãã®åé¡ã§ã¯ãããŸãããæ ¢æ§çãªã¹ãããªããªãæãéäžåã®äœäžãã©ãããããéãââããããããªããšãªãã®äžèª¿ãã®èæ¯ã«ãã现èå ã®ãšãã«ã®ãŒä»£è¬ã·ã¹ãã ãæ·±ãé¢ä¿ããŠããŸãã
ããã³ã³ããªã¢ã®ããšãã«ã®ãŒãäœãåãããµããŒãããããšã¯ãåãªãå¥åº·ç®¡çãè¶ ããŠãæ¥ã ã®ããã©ãŒãã³ã¹ãèŒããšããã人çã®è³ªãã®ãã®ãé«ããéžæãªã®ã§ãã
ãã©ãªãšããå°ããªå³¶åœã§å§ãŸã£ãåœå®¶ãããžã§ã¯ãã¯ãå®ã¯çŸä»£ç€ŸäŒãçããç§ãã¡å šå¡ã«ããšãŠã倧åãªåããæããããŠããŸãã
ãããªãã®çްèã¯ä»ããšãã«ã®ãŒããã¡ããšçãããŠããŸããïŒã
次åäºå ãæ¥œåãã©ãªãšçްèã®å¥è·¡â¢ãââ æ²»éšã®æåç·ããèŠããŠãããã®ãæ°å€ã®å€åãšã人ã ã®ã声ã ââ æ°åã ãã§ã¯èªããªãããã©ãªã®äººã ã®å€åãšã¯ãæ²»éšåå è ã®å£°ãšãç ç©¶è ãã¡ã次ã«èŠæ®ããæªæ¥ã«è¿«ããŸãã
ââïŒç¬¬3åãžç¶ãïŒ
ð¡ ãã®åœå®¶ãããžã§ã¯ãã®æåããä»ããããªãã®æ¥åžžã«
ããããç ç©¶ã¯ããŸã çºå±éäžã®éšåãå€ããããŸããããããã现èã®ãšãã«ã®ãŒä»£è¬ããšããèŠç¹ããå¥åº·ãèŠçŽãæµãã¯ãäžçäžã§å°ããã€åºããå§ããŠããŸãã
â 5-ALAã詊ãããæ¹ãž

5-ALAãéžæè¢ãšããŠèããŠããæ¹ãžã
æ¬é£èŒã¯ã5-ALAã補é ã»è²©å£²ããKIYAN PHARMAã®å ¬åŒã¢ãã£ãªãšã€ãããŒãããŒãšããŠãã¡ãŒã«ãŒçŽçµã®ç¹èšã«ãŒãããçšæããŠããŸãã
æµéãä»ããªãå ¬åŒã«ãŒãã®ãããèªè éå®ã§1,500ååŒããèªåé©çšãããŸãã
åããªããã°ããããŠãããããã ãã®ããšã§ãã
â· ãŸã詊ããŠã¿ããæ¹ïŒååïŒ
â»ç¶ããããšãåæã«ããæ¹ã¯å®æããåŸã§ã
â· ç¶ããããšãåæã«èããæ¹ïŒå®æã»1ç®±ïŒ
â· è€æ°ã§ã®ç¶ç¶ãèããæ¹ïŒå®æã»2ç®±ïŒ
â»äžèšã®ãªã³ã¯ããé²ããšãKIYAN PHARMAå ¬åŒè²©å£²ããŒãžãžçŽæ¥é·ç§»ããèªåã§1,500ååŒããé©çšãããŸãã
ãåºå žã»åèæç®ã
ïŒâ»1ïŒå 霢ã«äŒŽãäœå 5-ALAçç£éã®å€åã«é¢ããç ç©¶ããŒã¿ïŒã¡ãŒã«ãŒè³æã«ããïŒ
ïŒâ»2ïŒTanaka T. et al. "5-Aminolevulinic acid combined with sodium ferrous citrate ameliorates glucose tolerance via the enhancement of mitochondrial function." PLOS ONE, 2013.
SBIããŒã«ãã£ã³ã°ã¹æ ªåŒäŒç€ŸïŒ5-ALAã«é¢ãããã©ãªå ±ååœã§ã®ç³å°¿ç èšåºç ç©¶ã»æ²»éšãªãªãŒã¹
Wallace D.C. "Mitochondria and cancer." Nature Reviews Cancer, 2012.
Szendroedi J. et al. "The role of mitochondria in insulin resistance and type 2 diabetes mellitus." Nature Reviews Endocrinology, 2012.
#ãã©ãª #5ALA #ç³å°¿ç #ããã³ã³ããªã¢ #ãšãã«ã®ãŒä»£è¬ #è¡ç³å€ #åœå®¶ãããžã§ã¯ã #äºé²å»ç #现èããå¥åº·ã« #çºé µãã¯ãããžãŒ